4,6-diphenyl-1,3,5-thiadiazinane-2-thione | 53983-18-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻二嗪类
• 英文名称: 4,6-diphenyl-1,3,5-thiadiazinane-2-thione
• 英文别名: 4,6-diphenyl-[1,3,5]thiadiazinane-2-thione；4,6-diphenyl-tetrahydro-[1,3,5]thiadiazin-2-thione；4,6-Diphenyl-tetrahydro-[1,3,5]thiadiazin-2-thion；4,6-Diphenyl-tetrahydro-1,3,5-thiadiazin-2-thion
• CAS: 53983-18-9
• 化学式: C₁₅H₁₄N₂S₂
• 分子量: 286.422
• InChiKey: PPCOHTPXMURTDH-UHFFFAOYSA-N

物化性质

• 沸点：
  455.3±55.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  81.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  二硫化碳 、 苯甲醛 在 ammonium hydroxide 作用下， 以 乙醇 为溶剂， 生成 4,6-diphenyl-1,3,5-thiadiazinane-2-thione
  参考文献：
  名称：

  Augustin,M. et al., Zeitschrift fur Chemie, 1974, vol. 14, p. 270

  摘要：

  DOI：

文献信息

• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• KINASE PROTEIN BINDING INHIBITORS
  申请人：University Of Florida Research Foundation

  公开号：EP2136829A1

  公开（公告）日：2009-12-30
• IDO INHIBITORS
  申请人：Newlink Genetics

  公开号：EP2227233A2

  公开（公告）日：2010-09-15
• Kinase protein binding inhibitors
  申请人：Cance William G.

  公开号：US20090239850A1

  公开（公告）日：2009-09-24

  The invention relates to protein binding inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including cell proliferative disorders, especially cancer.
• US8404669B2
  申请人：——

  公开号：US8404669B2

  公开（公告）日：2013-03-26